Beijing News (Reporter Liu Xu) On April 6, the Hong Kong-listed company Kintor Pharmaceuticals announced the clinical data of new crown oral drugs. Prokalutamide is effective in reducing hospitalization/mortality.Today, the opening of Kintor Pharmaceuticals rose in a straight line, with an increase of more than 200% within two minutes of the opening. As of the close of the evening, Kintor Pharmaceutical reported HK$28.85 per share, an increase of 106.37%.
Global multicenter treatment of mild-to-moderate disease with proclutamideⅢPhase 1 clinical trial final analysis resultsIt was shown that prokalutamide can effectively reduce hospitalization/mortality, with a corresponding protection rate of 50% in subjects who took the drug for at least 1 day; and a corresponding protection rate of 100% in subjects who took the drug for more than 7 days. Prokalutamide also significantly reduced hospitalization/mortality in subjects with high risk factors (eg, advanced age, obesity, diabetes, hypertension, etc.). Prokalutamide can significantly and continuously reduce the new coronavirus load. Compared with the control group, the prokalutamide treatment group can significantly and continuously reduce the new coronavirus load from the 3rd day to the 28th day of administration. In terms of symptom improvement, the proclutamide group could better improve some of the related symptoms of new coronary pneumonia, such as fever, shortness of breath, and cough, compared with the control group, and the improvement continued to be better than the control group until at least the 28th day. In terms of safety, the overall tolerance of proclutamide in the treatment of mild to moderate COVID-19 subjects is good and safe and controllable.
Two new crown oral drugs have been approved for marketing in the world, namely Molnupiravir of Merck and Paxlovid of Pfizer. Although no domestically developed oral drugs for the new crown have been approved, many companies have entered the market.
Antibodies and small molecules are two conventional technical paths for new crown drug development. On December 8, 2021, the State Food and Drug Administration approved the listing of Tengsheng Biopharmaceutical Holdings’ subsidiary Tengsheng Huachuang’s ambavirumab injection and romisevirumab injection, becoming my country’s first new coronavirus with independent intellectual property rights Neutralizing antibody combination therapy drugs; in September 2021, Junshi Bio’s eltegravizumab and banivirumab double-antibody therapy received emergency use authorization from the U.S. Food and Drug Administration (FDA), adding prevention on the basis of treatment COVID-19 virus indications. In terms of antibody drugs alone, as of the end of 2021, there are nearly 30 COVID-19 neutralizing antibodies in the early research stage before Phase II clinical trials in China.
In terms of small molecule drugs, Junshi Bio’s drug VV116 has been approved for clinical use. On December 31, 2021, Junshi Bio announced that the Ministry of Health of Uzbekistan has granted emergency use authorization for its oral nucleoside anti-new coronavirus drug VV116 for the treatment of 2019 new coronary pneumonia. On January 10 this year, Yuekang Pharmaceutical announced that it signed a technology transfer contract with the Institute of Pathogen Biology, Chinese Academy of Medical Sciences to jointly develop a broad-spectrum coronavirus membrane fusion inhibitor polypeptide drug for novel coronavirus pneumonia. On January 14, Genting Xinyao announced that it will globally develop and commercialize a group of 3CL protease inhibitors from the Singapore Experimental Drug Research and Development Center, which is expected to become a class-leading oral anti-coronavirus drug.
Proofreading Liu Baoqing Return to Sohu, see more
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.